Background: A lack of effective diagnosis methods for
preclinical HCC has resulted in a low rate of early detection.
Aldo-keto reductase family 1 member B10 (AKR1B10) is
associated with several cancer types. Objective: Studying the
association of AKR1B10 with HCC and the probability of its
clinical utility for prognosis of HCC after treatment. Methods: A
cross sectional study was conducted on 120 subjects who were
divided into: group I; included 40 patients with HCC, group II;
included 40 patients with CLD and group III; included 40
apparently healthy subjects. All patients were subjected to
complete history taking thorough clinical examination. Complete
blood picture, liver enzymes, serum bilirubin, S. albumin, INR, S.
creatinine, S. AFP and S. AKR1B10 by ELISA- were done.
AKR1B10 was done before and one month after HCC ablation.
Pelvi-abdominal ultrasonography, multislice CT scan and/or
dynamic MRI- were done. Patients with HCC were treated by
TACE and RFA. Results: There is a statistically significant
decrease of AKR1B10 after treatment, in improved and failed
cases. ROC curve analysis for AKR1B10 before treatment is
good in differentiating between HCC and CLD groups
(AUC=0.728) at a cut off level of 2834.5. There is a statistically
significant decrease of AFP from before to after treatment
detected for HCC group. Conclusion: AKR1B10 is good for
diagnosis of HCC and could be used as a novel screening method
and its diagnostic efficacy for HCC is more when combined with
AFP